Columbus Circle Investors Purchases 91,142 Shares of Clovis Oncology, Inc. (CLVS)
Columbus Circle Investors boosted its position in Clovis Oncology, Inc. (NASDAQ:CLVS) by 74.4% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 213,674 shares of the biopharmaceutical company’s stock after purchasing an additional 91,142 shares during the quarter. Columbus Circle Investors owned about 0.44% of Clovis Oncology worth $17,607,000 at the end of the most recent quarter.
Other large investors have also recently modified their holdings of the company. Capital Analysts LLC bought a new stake in Clovis Oncology in the 3rd quarter valued at about $111,000. Phocas Financial Corp. bought a new stake in Clovis Oncology in the 2nd quarter valued at about $112,000. Cypress Capital Management LLC WY lifted its position in Clovis Oncology by 272.7% in the 3rd quarter. Cypress Capital Management LLC WY now owns 2,050 shares of the biopharmaceutical company’s stock valued at $169,000 after purchasing an additional 1,500 shares during the last quarter. Advisors Asset Management Inc. lifted its position in Clovis Oncology by 160.7% in the 2nd quarter. Advisors Asset Management Inc. now owns 1,895 shares of the biopharmaceutical company’s stock valued at $177,000 after purchasing an additional 1,168 shares during the last quarter. Finally, PNC Financial Services Group Inc. lifted its position in Clovis Oncology by 3.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 2,800 shares of the biopharmaceutical company’s stock valued at $179,000 after purchasing an additional 100 shares during the last quarter. Hedge funds and other institutional investors own 98.53% of the company’s stock.
Clovis Oncology, Inc. (NASDAQ:CLVS) traded down $3.67 during midday trading on Friday, hitting $63.21. 1,440,000 shares of the company were exchanged, compared to its average volume of 1,290,736. The company has a debt-to-equity ratio of 0.94, a quick ratio of 3.16 and a current ratio of 3.19. Clovis Oncology, Inc. has a twelve month low of $33.23 and a twelve month high of $99.45.
Clovis Oncology (NASDAQ:CLVS) last released its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.24) EPS for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.06). Clovis Oncology had a negative return on equity of 122.06% and a negative net margin of 947.47%. The business had revenue of $16.81 million during the quarter, compared to the consensus estimate of $21.12 million. During the same quarter in the previous year, the firm earned ($1.70) earnings per share. research analysts expect that Clovis Oncology, Inc. will post -7.63 EPS for the current fiscal year.
In related news, insider Gillian C. Ivers-Read sold 3,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $63.70, for a total value of $191,100.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 9,000 shares of company stock worth $653,220 over the last quarter. Insiders own 12.50% of the company’s stock.
CLVS has been the topic of several recent research reports. Cann reiterated a “hold” rating on shares of Clovis Oncology in a research report on Monday, July 31st. J P Morgan Chase & Co reiterated an “overweight” rating on shares of Clovis Oncology in a research report on Tuesday, August 1st. BidaskClub upgraded shares of Clovis Oncology from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, August 2nd. Bank of America Corporation reiterated a “buy” rating on shares of Clovis Oncology in a research report on Thursday, August 3rd. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $93.00 price objective on shares of Clovis Oncology in a research report on Thursday, August 10th. Eight equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Clovis Oncology has a consensus rating of “Buy” and a consensus target price of $86.15.
About Clovis Oncology
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Receive News & Stock Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related stocks with our FREE daily email newsletter.